Financings

ADC Therapeutics SA set terms for its proposed $200 million IPO and will offer approximately 8.2 million common shares priced between $23 and $26 each.

Amphivena Therapeutics Inc. closed on a $62 million series C round.

Amryt Pharma plc raised $60 million in new equity financing to complete its all-stock takeover of Aegerion Pharmaceuticals Inc.

Aprea Therapeutics Inc., a portfolio company of Karolinska Development AB, set terms for its proposed IPO, seeking to raise $75 million by offering 5 million shares priced in a range of $14 to $16 each.

Biontech SE has filed a registration statement to offer 13.2 million American depositary shares (ADSs) representing its ordinary shares to the public. The IPO price is expected to be between $18 and $20 per ADS, and the raise is expected to be approximately $250 million at the midpoint of the range.

Bioxcel Therapeutics Inc. said it priced an underwritten public offering for gross proceeds of approximately $19 million.

Celltrion Group and Korea Development Bank have agreed to run a fund worth KRW220 billion (US$184 million) to grow venture companies in Korea's bio-health care sector.

Frequency Therapeutics Inc. disclosed terms for its IPO, seeking to raise $101 million by offering 6.7 million shares priced in range of $14 to $16.

Gaba Therapeutics Inc. closed on a series A round of up to $15.5 million.

IGM Biosciences Inc. closed its IPO of approximately 12.6 million common shares, priced at $16 apiece, including the full exercise by underwriters of the overallotment option to purchase approximately 1.6 million additional shares. The IPO generated gross proceeds of approximately $201.3 million.

Meissa Vaccines Inc. completed a $30 million series A round.

Provention Bio Inc. said its follow-on financing and private placement generated total net proceeds of $62.7 million.

Spark Biopharma Inc. has secured KRW25 billion (US$21 million) in series B funding.

T3 Pharmaceuticals AG raised more than CHF12 million (US$12.1 million) in a second financing round.

VBI Vaccines Inc. closed its underwritten public offering for gross proceeds of $40.3 million.

Vedanta Biosciences Inc. raised $16.6 million in a series C-2 financing, bringing the amount of its C round to $62.1 million.

Zielbio Inc. closed on a $25.1 million series A financing round.

Deals

Blade Therapeutics Inc. said it acquired Atxco Inc., including its core asset, PAT-409, a phase I-ready autotaxin inhibitor for patients with fibrotic diseases.

Boehringer Ingelheim GmbH has agreed to pay Inflammasome Therapeutics Inc. as much as $160 million for rights to use its intravitreal drug delivery technology with up to three Boehringer compounds.

Cancer Research UK disclosed partnerships with Deep Science Ventures and Panacea Charitable Trust to kick-start the charity's first initiative to promote entrepreneurship.

Clovis Oncology Inc. entered a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH to develop a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein alpha.

Evotec SE and Takeda Pharmaceutical Co. Ltd. are partnering to develop at least five drug programs.

I-Mab Biopharma Co. Ltd. signed a clinical research collaboration agreement with Merck & Co. Inc. to evaluate the combination of I-Mab's TJC-4 and Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with multiple cancer types.

Moderna Inc. established a multiyear research collaboration with Harvard University, with the goal of identifying and developing therapeutic approaches targeting immunological diseases.

Neucyte Inc. entered an exclusive agreement with Trillium Therapeutics Inc. to advance an undisclosed preclinical compound with potential use in treating refractory epilepsy in the form of Dravet syndrome and related disorders.

Proteon Therapeutics Inc. entered a merger deal with Artara Therapeutics Inc., a startup that is focused on TARA-002, a therapy for lymphatic malformations (also called lymphangiomas) that has already gained validation by way of a similar product in Japan.

QED Therapeutics Inc., a subsidiary of Bridgebio Pharma Inc., is collaborating with The Ivy Brain Tumor Center to study infigratinib, an FGFR1-3 tyrosine kinase inhibitor, for the treatment of glioblastoma.

...And more

Abeona Therapeutics Inc.'s shares fell after the FDA put a clinical hold on a phase III study of its autologous cell therapy for recessive dystrophic epidermolysis bullosa.

Deerfield Management Co. LP is investing $635 million to create a life sciences campus in New York, designed to integrate capabilities from academia, government, industry and not-for-profit entities.

Dance Biopharm Inc. said it is rebranding as Aerami Therapeutics Inc. and moving its headquarters to Durham, N.C.

Eyegate Pharmaceuticals Inc. regained compliance with the Nasdaq listing rule concerning minimum bid price.

Hong Kong Polytechnic University has developed a new class of antibiotic drug candidates, called Nusbiarylins, which inhibit the interaction of NusB and NusE that is crucial for synthesis of bacterial ribosomal RNA.

Novo Nordisk A/S' Rybelsus won FDA approval at 7-mg and 14-mg doses to improve control of blood sugar in adults with proper diet and exercise.

Oncolytics Biotech Inc. received a notification letter from Nasdaq that it was not compliant with the minimum bid price requirement for continued listing.

Rexahn Pharmaceuticals Inc. is exploring strategic alternatives, including the possibility of an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions.

The FDA has granted approval for the first live, non-replicating vaccine to prevent smallpox and monkeypox developed by Bavarian Nordic A/S and branded as Jynneos.

Versatope Therapeutics Inc., a company developing a universal influenza vaccine has been awarded a contract with the National Institute of Allergy and Infectious Diseases worth up to $17.9 million over five years to support completion of a phase I study.

Whole Biome Inc. changed its corporate name to Pendulum Therapeutics Inc. to reflect a broader commitment to developing therapeutic solutions that affect human health through microbiome interventions.

No Comments